Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy

 
• By Jessica Merrill

The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.

test tube

More from Deals

More from Business